Trials / Completed
CompletedNCT05481736
Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- COMPASS Pathways · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy and Safety of COMP360 Psilocybin therapy in Anorexia Nervosa: a Proof-of-concept Study
Detailed description
This study aims to explore the efficacy and safety of COMP360 25 mg as compared to COMP360 1 mg (control condition) administered with psychological support in participants with Anorexia Nervosa
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Psilocybin | COMP360 Psilocybin administered under supportive conditions |
Timeline
- Start date
- 2022-10-12
- Primary completion
- 2024-11-18
- Completion
- 2024-11-18
- First posted
- 2022-08-01
- Last updated
- 2024-12-04
Locations
5 sites across 3 countries: United States, Ireland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05481736. Inclusion in this directory is not an endorsement.